Besides the role in angiogenesis, the immunomodulatory role of VEGF-A in various cancers including HCC makes VEGF inhibitors an ideal combinatorial candidate with ICI in immunotherapy. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.